Profusa (PFSA) Cash from Investing Activities (2022 - 2026)
Profusa's (PFSA) quarterly Cash from Investing Activities came in at $1.1 million in Q1 2026, down 82.36% year-on-year from $6.5 million in Q1 2025, and up 213.59% quarter-over-quarter from -$1.0 million in Q4 2025.
Profusa (PFSA) Cash from Investing Activities (2022 - 2026) Analysis & Trends
Profusa's Cash from Investing Activities history runs 5 years deep, the most recent figure standing at $1.1 million for Q1 2026.
- On a quarterly basis, Cash from Investing Activities fell 82.36% year-over-year to $1.1 million in Q1 2026; TTM through Mar 2026 was -$7.4 million, a 206.55% decrease from a year earlier, with the FY2025 full-year figure at -$2.0 million, down 167.66% from the prior year.
- Cash from Investing Activities rose to $1.1 million in Q1 2026 per PFSA's latest filing, from -$1.0 million in the prior quarter.
- Across five years, Cash from Investing Activities topped out at $185.7 million in Q1 2023 and bottomed at -$7.5 million in Q3 2025.
- The 5-year median for Cash from Investing Activities is $32631.5 (2024), against an average of $13.4 million.
- Across the five-year window, Cash from Investing Activities plunged 206421.62% in 2023 and surged 699.29% in 2024, its largest moves.
- Year by year, Cash from Investing Activities stood at -$37.0 in 2022, then plunged by 206421.62% to -$76413.0 in 2023, then jumped by 699.29% to $457936.0 in 2024, then sank by 320.12% to -$1.0 million in 2025, then soared by 213.59% to $1.1 million in 2026.
- Per Business Quant, the three latest PFSA Cash from Investing Activities figures stand at $1.1 million (Q1 2026), -$1.0 million (Q4 2025), and -$7.5 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 181.51 Bn | 174.22 Bn | 6.27 Bn | -20.32 Bn |
| 2 | Stryker | 128.20 Bn | 125.32 Bn | 3.81 Bn | -185.00 Mn |
| 3 | Medtronic | 107.69 Bn | 98.47 Bn | 6.41 Bn | -917.00 Mn |
| 4 | Boston Scientific | 68.05 Bn | 66.59 Bn | 3.61 Bn | -591.00 Mn |
| 5 | Edwards Lifesciences | 47.52 Bn | 43.85 Bn | 1.29 Bn | -92.80 Mn |
| 6 | GE HealthCare Technologies | 28.46 Bn | 26.17 Bn | 1.98 Bn | -2.50 Bn |
| 7 | Dexcom | 28.25 Bn | 27.13 Bn | 750.30 Mn | -298.50 Mn |
| 8 | Smith & Nephew | 26.73 Bn | 26.15 Bn | - | - |
| 9 | Koninklijke Philips | 25.31 Bn | 22.19 Bn | 2.07 Bn | -475.32 Mn |
| 10 | Profusa | 84,405.00 | -290,595.00 | - | 1.15 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.15 Mn |
| Mar 31, 2026 | 1.15 Mn |
| Dec 31, 2025 | -1.01 Mn |
| Dec 31, 2025 | -1.01 Mn |
| Sep 30, 2025 | -7.49 Mn |
| Sep 30, 2025 | -7.49 Mn |
| Jun 30, 2025 | -1.00 |
| Jun 30, 2025 | -1.00 |
| Mar 31, 2025 | 6.49 Mn |
| Mar 31, 2025 | 6.49 Mn |
| Dec 31, 2024 | 457,936.00 |
| Dec 31, 2024 | 457,936.00 |
| Sep 30, 2024 | -112,115.00 |
| Sep 30, 2024 | -112,115.00 |
| Jun 30, 2024 | 65,264.00 |
| Jun 30, 2024 | 65,264.00 |
| Mar 31, 2024 | 2.56 Mn |
| Mar 31, 2024 | 2.56 Mn |
| Dec 31, 2023 | -76,413.00 |
| Dec 31, 2023 | -76,413.00 |